1Yanagisawa M, Karihara H, Kimura S, et al. A novel potent vasoconstrictorpeptide produced by vascular endothelial cell[ J ]. Nature,1988,322(31 ) :411 -415.
2Nelson J B, Chan-Tack K, Hedican S P, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer [ J ]. Cancer Res, 1996, 56 (4) : 663 - 668.
3Bagnato A,Tecce R, Di Castro V, et al. Activation of mitogenic signaling by endothelin-1 in ovzrian carcinoma cells [J]. Cancer Res,1997,57(7) :1306- 1311.
4Rosano L,Sipnella F,Di Castro V,et al. Endothelin receptor blockade inhibits molecular effectors of tumor invasion in Kaposi's sarcoma [J]. Am J Pathol,2003,163(2) :753 -762.
5Nelson J B,Nabulsi A A, Vogelzang N J, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist [ J ]. J Urol, 2003,169 (3) : 1143 - 1149.
6Carducci M A,Padley R J,Breul J,et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized,phase Ⅱ, placebo-controlled trial [ J ]. J Clin Oncol,2003,21 (4) :679 -689.
7Yuyama H, Koakutsu A, Fujiyasu N, et al. Effects of selective endothelin ETA receptor antagonists on endothelin induced potentiation of cancer pain [ J ]. Eur J Pharmacd, 2004,492 (2 - 3 ) : 177 - 182.
8Curwen J O, Wilson C, ZD4054:a specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease [ J ]. Eur J Cancer,2002,38 ( Suppl 7) :S102 - S102.
9Curtis N, Howard Z, Brooks N, et al. ZD4054 specifically inhibits ednothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects [J]. Eur J Cancer Suppl,2004,2(8) :27.
2[1]Grandis JR,Melham MF,Gooding WE,et al.Levels of TGF-αand EGFR protein in head and neck squamous cell carcinoma and patient survival.J Natl Cancer Inst (Bethesda),1998,90(11)∶824-832.
3[2]Ryan PD,Chabner BA.On receptor inhibitors and chemotherapy.Clin Cancer Res,2000,6(12)∶4607-4609.
4[3]Mendelsohn J.Blockade of receptors for growth factors:An anticancer therapy-The fourth annual Joseph H.Burchenal American Association for Cancer Research Clinical Research Award Lecture.Clin Cancer Res,2000,6(3)∶747-53.
5[4]Inoue K,Slaton JW,Perrotte P,et al.Paclitaxel enhance the effect of the anti-epidermal growth factor receptor monoclonal antibody Imclonec225 in mice with metastatic human bladder transitional cell carcinoma.Clin Cancer Res,2000,6(12)∶4874-4884.
6[5]Baselga J,Norton L,Masui H,et al.Antitumor effects of doxorubicin in combination with anti-epidernal growth factor receptor monoclonal antibodies.J Natl Cancer Inst,1993,85(16)∶1327-1333.
7[6]Fan Z,Baselga J,Masui H,et al.Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.Cancer Res,1993,53(19)∶4637-4642.
8[7]Bruns C,Harbison M,Davis D,et al.Epidermal growth factor receptor blockede with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing othotopically in nude mice by antiangiogenic mechanisms.Clin Cancer Res,2000,6(5)∶1936-1948.
9[8]Baselga J,Pfister D,Cooper M,et al.Phase Ⅰ studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and combination with cisplatin.J Clin Oncol,2000,18(4)∶904-914.
10[9]Mendelson J,Shin DM,Donato N,et al.Targeted therapy with C225 and cisplatin in patients with head and neck cancers.Clin Cancer Res,2001,7(5)∶1204-1213.
